Worth reading
57In focus
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
24.1
Year-on-year change in revenue (%)Wording
Conditional
How definitive the wording is.Results for this period
Interim period (second quarter)2025年4月1日〜2025年9月30日ConsolidatedJapanese GAAPNet Sales5,123¥ millionYear on year +24.1%Progress 46.6%
Operating profit103¥ millionYear on year -56.0%Progress 16.9%
Ordinary income100¥ millionYear on year -58.2%Progress 17.9%
Net income attributable to owners of the parent-10¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share¥(2.25)
Financial position at period-end
Total assets10,361¥ million
of which net assets 3,539 ¥ millionEquity ratio 32.7%vs. prior year-end -1.1pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Cash inflows and outflows
Operating+80,290
Investment-573,736
Financials-360,313
Net change-853,759
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Cash and cash equivalents at end of period¥1,841,947 thousand
Segment revenueMedical Business ¥1,189,667 thousand, Platform Business ¥1,677,293 thousand (YoY -2.2%), Broadband business ¥1,805,484 thousand (YoY -3.6%), SaaS and DX Business ¥451,296 thousand (YoY +0.5%)
Segment profitMedical Business ¥-124,809 thousand, Platform Business ¥193,381 thousand (YoY -34.4%), Broadband business ¥269,355 thousand (YoY -8.6%), SaaS and DX Business ¥-44,159 thousand
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥11,000 million (YoY +21.0%)
Operating profit¥610 million (YoY +30.9%)
Ordinary income¥560 million (YoY +57.8%)
Net income¥320 million (YoY +73.8%)
Revision to Earnings ForecastNet Sales ¥11,000 million → ¥11,000 million（0.0%） / Operating profit ¥610 million → ¥610 million（0.0%） / Ordinary income ¥560 million → ¥560 million（0.0%） / Net income ¥320 million → ¥320 million（0.0%）
Annual Dividend Forecast¥30 → ¥31.5（+5.0%）
Factors Behind Changes in Business Performance
メディカル事業では診療科目の拡大により大幅増収となった。プラットフォーム事業ではメディアサービスの広告単価下落、ブロードバンド事業では課金会員数の伸び悩みが減収減益要因となった。SaaS・DX事業ではSaaSサービスの成長がDXサービスの減収を補った。親会社株主に帰属する中間純損益は本社移転費用等の特別損失により赤字となった。
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noneそれ以外の変更 None見積りの変更 None修正再表示 None
Changes in the scope of consolidationNew Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed
Material subsequent eventsNo applicable matters
Impairment lossNo applicable matters
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of property, plant and equipment ¥12,920 thousand / Extraordinary loss Head Office Relocation Costs ¥68,690 thousand, Business Exit Losses ¥33,135 thousand, Other ¥0 thousand
Depreciation and amortization¥128,523 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingWhether applicable Yes / Subject person Institutional investors and analysts
Issued Shares at Period-End4,873,430
Treasury Shares at Period-End74,000
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2025年4月1日〜2025年9月30日 |
| Net Sales | ¥5,123 million (YoY +24.1%) |
| Operating profit | ¥103 million (YoY -56.0%) |
| Ordinary income | ¥100 million (YoY -58.2%) |
| Profit attributable to owners of the parent | ¥-10 million |
| Net income per share | ¥(2.25) |
| Equity ratio | End of the current fiscal period 32.7 / End of previous period 33.8 |
| Total assets | ¥10,361 million |
| Net assets | ¥3,539 million |
| Cash flows from operating activities | ¥80,290 thousand |
| Cash flows from investing activities | ¥-573,736 thousand |
| Cash flows from financing activities | ¥-360,313 thousand |
| Cash and cash equivalents at end of period | ¥1,841,947 thousand |
| Full-year earnings forecast | Net Sales ¥11,000 million (YoY +21.0%) / Operating profit ¥610 million (YoY +30.9%) / Ordinary income ¥560 million (YoY +57.8%) / Net income ¥320 million (YoY +73.8%) |
| Revision to Earnings Forecast | Net Sales ¥11,000 million → ¥11,000 million（0.0%） / Operating profit ¥610 million → ¥610 million（0.0%） / Ordinary income ¥560 million → ¥560 million（0.0%） / Net income ¥320 million → ¥320 million（0.0%） |
| Annual Dividend Forecast | ¥30 → ¥31.5（+5.0%） |
| Segment revenue | Medical Business ¥1,189,667 thousand, Platform Business ¥1,677,293 thousand (YoY -2.2%), Broadband business ¥1,805,484 thousand (YoY -3.6%), SaaS and DX Business ¥451,296 thousand (YoY +0.5%) |
| Segment profit | Medical Business ¥-124,809 thousand, Platform Business ¥193,381 thousand (YoY -34.4%), Broadband business ¥269,355 thousand (YoY -8.6%), SaaS and DX Business ¥-44,159 thousand |
| Depreciation and amortization | ¥128,523 thousand |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of property, plant and equipment ¥12,920 thousand / Extraordinary loss Head Office Relocation Costs ¥68,690 thousand, Business Exit Losses ¥33,135 thousand, Other ¥0 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | New Number of companies 0 / Company name Not disclosed / Excluded Number of companies 0 / Company name Not disclosed |
| Material subsequent events | No applicable matters |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Whether applicable Yes / Subject person Institutional investors and analysts |
| Issued Shares at Period-End | 4,873,430 |
| Treasury Shares at Period-End | 74,000 |
| Factors Behind Changes in Business Performance | メディカル事業では診療科目の拡大により大幅増収となった。プラットフォーム事業ではメディアサービスの広告単価下落、ブロードバンド事業では課金会員数の伸び悩みが減収減益要因となった。SaaS・DX事業ではSaaSサービスの成長がDXサービスの減収を補った。親会社株主に帰属する中間純損益は本社移転費用等の特別損失により赤字となった。 |
Items this document does not state (5)
Operating MarginPayout ratioShareholder Return PolicyRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.メディカル事業で診療科目が拡大し大幅増収となった一方、メディアサービスで広告単価が下落した。さらに、本社移転費用および事業撤退損を特別損失に計上した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.